Improving upon exciting radionuclide therapy in neuroendocrine tumours

There is a great deal of excitement in the oncology field over the use of peptide receptor radionuclide therapy with lutetium-177 (177Lu)-octreotate for the treatment of patients  with neuroendocrine tumours following the positive results of the phase III NETTER-1 trial.
Targeted Oncology